Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) announced that founder and CEO R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference at The Westin New York Grand Central in New York City on September 9, 2026, at 8:45 a.m. Eastern Time. Management will also hold a Q&A session and be available for one-on-one meetings with institutional investors during the conference.
Positive
- None.
Negative
- None.
Market Reaction – VVOS
Following this news, VVOS has declined 15.82%, reflecting a significant negative market reaction. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner has triggered 40 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.17. Trading volume is exceptionally heavy at 248.4x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 28 | Regional center agreement | Positive | -13.0% | Signed agreements to launch a regional sleep testing and treatment center |
| Aug 25 | Referral growth update | Positive | -5.8% | Reported 212% growth in average weekly new patient referrals |
| Aug 20 | Facility opening announcement | Positive | +1.2% | Announced Henderson facility expected to exceed $10 million annual capacity |
| Aug 14 | Quarterly earnings report | Negative | -12.3% | Reported higher revenue alongside larger losses and limited cash |
| Aug 14 | Earnings release schedule | Neutral | +12.4% | Scheduled second-quarter results and an investor conference call |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational announcements were followed by negative 24-hour reactions in two of three cases, while the earnings release also had a negative reaction.
Key Terms
obstructive sleep apnea medical
osa medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, taking place September 9 and 10, 2026, at The Westin New York Grand Central in New York City.
Mr. Huntsman is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. Eastern Time, followed by a question-and-answer session. Company management will also be available for one-on-one meetings with institutional investors throughout the conference.
"Given the significant and positive trends that our business has been taking over the past few months, this is a perfect time to get our message out to the financial markets," said Mr. Huntsman. "We look forward to visiting with investors and telling our amazing story."
Investors interested in scheduling a meeting with Vivos management should contact their Moody Capital Solutions representative or the Company at the contact listed below.
Investor Relations Contact:
Jennifer Hauser
Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312338